All Trials

A Randomized, Open-label, Two-arm, Multicenter Phase 2 Study to Evaluate Efficacy and Safety of PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab Monotherapy in Patients With Recurrent or Metastatic Cervical Cancer.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with PD-L1–positive, HPV16/18-positive recurrent or metastatic cervical cancer who have progressed on prior pembrolizumab (≤2 prior systemic regimens) are randomized to pembrolizumab alone versus pembrolizumab plus PRGN-2009, an investigational gorilla adenoviral therapeutic vaccine targeting HPV16/18 E6/E7 to enhance HPV-specific T-cell responses. Key endpoints include ORR, with additional safety and survival outcomes; notable exclusions include active CNS disease and other active malignancies.

ClinicalTrials.gov ID: NCT06157151

DESTINY-Endometrial01: An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with HER2 IHC 3+/2+, pMMR primary advanced or recurrent endometrial carcinoma (systemic therapy–naïve in the advanced/recurrent setting; carcinosarcoma allowed) are randomized to T-DXd plus rilvegostomig (bispecific PD-1/TIGIT antibody) or T-DXd plus pembrolizumab versus carboplatin/paclitaxel plus pembrolizumab, with PFS as the primary endpoint. T-DXd is an anti-HER2 antibody–drug conjugate delivering a topoisomerase I inhibitor (DXd); key exclusions include prior ICIs/ADCs and significant ILD/pneumonitis risk.

ClinicalTrials.gov ID: NCT06989112

A Phase II, Multi-Center Study to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination With Anti-cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors in three cohorts: recurrent/metastatic cervical cancer after 1–2 prior lines; recurrent/metastatic HNSCC (including PD-L1–positive, systemic-therapy–naive or platinum-refractory); and untreated R/M HNSCC receive volrustomig, a bispecific PD-1/CTLA-4 antibody, as monotherapy or combined with chemo (carboplatin/paclitaxel or 5-FU plus platinum). Excludes prior checkpoint inhibitor exposure and requires ECOG 0–1 and PD-L1 testing; endpoints include ORR and safety per RECIST 1.1.

ClinicalTrials.gov ID: NCT06535607

A Phase 2 Multicohort Study to Evaluate Lorigerlimab in Participants With Advanced Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with platinum‑resistant high‑grade serous ovarian/primary peritoneal/fallopian tube cancer or clear cell gynecologic cancers (ovarian, endometrial, vaginal, vulvar, cervical) with measurable disease after prior lines of therapy; excludes prior PD‑1/PD‑L1/PD‑L2 or CTLA‑4 exposure and platinum‑refractory disease. Patients receive lorigerlimab (MGD019), an investigational bispecific checkpoint inhibitor targeting PD‑1 and CTLA‑4, given IV every 21 days until progression or intolerance.

ClinicalTrials.gov ID: NCT06730347

A Phase 2 Study of Ivonescimab (Bispecific Antibody Against PD1 and VEGF) For the Treatment of Endometrial (EC) and Cervical (CC) Cancers

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Single-arm study of ivonescimab, a tetravalent bispecific antibody targeting PD‑1 and VEGF, in adults with metastatic or recurrent endometrial or cervical cancer that has progressed after at least one platinum regimen; prior PD‑1 or VEGF therapy allowed, ECOG 0–2, measurable disease required. Ivonescimab is given IV every 3 weeks for up to 24 months, aiming to combine immune checkpoint blockade with anti‑angiogenesis; primary endpoint is RECIST ORR.

ClinicalTrials.gov ID: NCT06925724

An Open-label, Multi-Center, Phase 2 Clinical Trial Evaluating Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel, and a Substudy Evaluating PIKTOR With Paclitaxel Plus an Insulin-Suppressing Diet, in Patients With Advanced or Recurrent Endometrial Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced or recurrent endometrioid endometrial carcinoma harboring a PI3K/AKT/mTOR pathway alteration, post 1–4 prior regimens including platinum and typically a checkpoint inhibitor, receive sapanisertib (mTORC1/2 inhibitor) plus serabelisib (PI3Kα inhibitor) combined with paclitaxel; a substudy adds an insulin‑suppressing diet. Key exclusions include uncontrolled CNS disease, significant cardiac issues, CYP3A modulator use, gastric pH–raising meds, QTc >480 ms, and poorly controlled diabetes or insulin use.

ClinicalTrials.gov ID: NCT06463028

A Phase 2 Study of Avelumab in Combination With ATR Inhibitor M1774 in Patients With ARID1A-mutated Recurrent Endometrial Cancer Who Have Received Prior Immunotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Enrolling adults with recurrent endometrial cancer harboring ARID1A loss‑of‑function mutations who have previously received PD‑1/PD‑L1 therapy; prior chemotherapy required, ECOG 0–2. Single-arm treatment is avelumab (anti–PD‑L1 mAb) plus M1774/tuvusertib, an oral ATR kinase inhibitor targeting DNA damage response to exploit synthetic lethality in ARID1A‑mutant tumors.

ClinicalTrials.gov ID: NCT06518564

A Phase 2/3 Study of Navtemadlin as Maintenance Therapy in Subjects With TP53WT Advanced or Recurrent Endometrial Cancer Who Responded to Chemotherapy

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with TP53 wild-type advanced or recurrent endometrial cancer who achieved CR/PR after first-line taxane–platinum chemotherapy (ECOG 0–1) are randomized to maintenance navtemadlin vs observation/placebo. Navtemadlin (KRT-232) is an oral MDM2 inhibitor that restores p53 signaling; given Days 1–7 of 28-day cycles, with cytopenias and GI AEs as key class toxicities.

ClinicalTrials.gov ID: NCT05797831

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4 Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with B7-H4–positive recurrent/metastatic endometrial carcinoma or carcinosarcoma after platinum and anti–PD-1/PD-L1 therapy (≤2 prior lines) are randomized to the B7-H4–targeted antibody–drug conjugate puxitatug samrotecan (AZD8205, delivers a topoisomerase I inhibitor payload) every 3 weeks versus physician’s choice single-agent chemotherapy (doxorubicin or paclitaxel). Key exclusions include prior TOP1 inhibitor or B7-H4–targeted therapy, ILD/pneumonitis, and platinum-sensitive (>12 months) recurrence without subsequent platinum in the recurrent setting.

ClinicalTrials.gov ID: NCT07044336

A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: For adults with pMMR advanced or recurrent endometrial carcinoma who have not progressed after first-line chemoimmunotherapy (carboplatin/taxane plus pembrolizumab), this trial randomizes maintenance pembrolizumab with or without sacituzumab tirumotecan. Sacituzumab tirumotecan is a TROP2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor payload.

ClinicalTrials.gov ID: NCT06952504